Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer

Trastuzumab has been shown to improve the survival outcomes of HER2 positive breast cancer patients. However, a significant proportion of HER2-positive patients are either inherently resistant or develop resistance to trastuzumab. We assessed the effects of neratinib, an irreversible panHER inhibito...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Canonici, Alexandra, Gijsen, Merel, Mullooly, Maeve, Bennett, Ruth, Bouguern, Noujoude, Pedersen, Kasper, O'Brien, Neil A, Roxanis, Ioannis, Li, Ji-Liang, Bridge, Esther, Finn, Richard, Slamon, Dennis, McGowan, Patricia, Duffy, Michael J., O'Donovan, Norma, Crown, John, Kong, Anthony
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2013
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3858548/
https://ncbi.nlm.nih.gov/pubmed/24009064
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares